- About Overview
- Honors and Awards
- Facts and Figures
- Support the School
- Contact Us
- Dean’s Office
- Dean’s Office Overview
- Education Unit
- Office of Faculty Academic Affairs
- Office of Administration
- Org Chart
- Patient Care
Antibody Network partners with Celgene to develop cancer therapies
By UCSF School of Pharmacy Editorial Staff / Tue Sep 15, 2015
A new collaboration between Celgene Corp. and the Recombinant Antibody Network (RAN) will support the development of next-generation, antibody-based cancer therapies. The RAN is a consortium comprising researchers from the UCSF School of Pharmacy (UCSF Antibiome Center), the University of Chicago, and the University of Toronto.
In this first industry partnership for the RAN, Celgene agreed to pay $25 million for the option to enter into future license agreements to develop and commercialize promising therapeutic antibodies to cancer-related targets.
“The RAN consortium has developed an automated antibody-engineering pipeline that enables high-throughput generation and validation of high-performance recombinant antibodies, at an unprecedented scale,” James Wells, PhD, a founding member of the RAN and chair of the School’s Department of Pharmaceutical Chemistry, which houses the Antibiome Center.
“This is a unique opportunity to partner with a top biopharmaceutical company to exploit these capabilities on extracellular targets in the discovery and development of new therapies for treating cancer,” said Wells.
About the School: The UCSF School of Pharmacy is a premier graduate-level academic organization dedicated to improving health through precise therapeutics. It succeeds through innovative research, by educating PharmD health professional and PhD science students, and by caring for the therapeutics needs of patients while exploring innovative new models of patient care. The School was founded in 1872 as the first pharmacy school in the American West. It is an integral part of UC San Francisco, a leading university dedicated to promoting health worldwide.